No association between proton pump inhibitor use and risk of dementia: Evidence from a meta‐analysis. Issue 1 (29th August 2019)

• Record Type: Journal Article
• Authors: Hussain, Salman; Singh, Ambrish; Zameer, Saima; Jamali, Mohammad Chand; Baxi, Harveen; Rahman, Syed Obaidur; Alam, Mahtab; Altamish, Mohammad; Singh, Avinash Kumar; Anil, Dasari; Hussain, Md Sarfaraj; Ahmad, Adil; Najmi, Abul Kalam
• Is Part Of: Journal of gastroenterology and hepatology. Volume 35:Issue 1(2020)
• Page Start: 19
• Page End: 28
• Publication Date: 2019-08-29
• Subjects: Alzheimer's disease -- dementia -- meta‐analysis, omeprazole -- PPI; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.14789
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: A growing body of literature suggests the association between dementia risk and proton pump inhibitor (PPI) use. Therefore, we aimed to investigate the association between PPI use and dementia risk. Methods: An extensive literature search was performed in PubMed, Embase, and Cochrane till March 31, 2019. All the studies (cohort and case–control) assessing the association between PPI use and dementia risk were eligible for inclusion. Articles were selected based on the screening of title and abstract, data were extracted, and risk of bias was assessed using Newcastle–Ottawa scale. The primary outcome was pooled risk of dementia among PPI user as compared with non‐PPI user. Secondary outcomes include dementia risk based on subgroups. Statistical analysis was performed using review manager software. Results: Twelve studies (eight cohort and four case–control) were found to be eligible for inclusion. Majority of the studies were of high quality. Dementia was diagnosed based on International Classification of Diseases 9/10 codes in majority of the included studies. PPI use was not associated with the dementia risk, with a pooled relative risk (RR) of 1.05 (95% confidence interval [CI]: 0.96–1.15), P = 0.31. Subgroup analysis based on study design (cohort: P = 0.14; case–control: P = 0.14), sex (RR 1.25 [95% CI: 0.97–1.60], P = 0.08), histamine 2 receptor antagonist blockers ( P = 0.93), and Alzheimer's disease (RR 1.00 [95% CI: 0.91–1.09], P = 0.93) revealed no significant association between PPI use and dementia risk. Conclusion: We found no significant association between PPI use and the risk of dementia or Alzheimer's disease.